Mirion Technologies (MIR) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenues rose 5% year-over-year to $207.1M, with both Medical and Technologies segments contributing to growth and margin expansion.

• Adjusted EBITDA for Q2 was $48.8M, up 10.2% year-over-year, with margin expanding to 23.6%.

• Net loss narrowed to $12.0M from $28.4M in Q2 2023, and operating income improved to $2.3M.

• Signed a major strategic partnership with EDF for nuclear new build projects, strengthening long-term positioning.

• Completed redemption of all public and private warrants and refinanced debt, improving capital structure.

Financial highlights

• Q2 2024 revenue was $207.1M, up 5% year-over-year (organic +3.6%, acquisition +1.8%, FX -0.4%).

• Adjusted EBITDA was $48.8M (23.6% margin), up from $44.3M (22.5%) in Q2 2023.

• Adjusted EPS was $0.10, up from $0.08 in Q2 2023; GAAP net loss per share was $0.06, improved from $0.14.

• Gross profit for Q2 was $97.4M (47.0% margin), up from $88.0M (44.7%) in Q2 2023.

• Adjusted free cash flow for Q2 was $8.9M, with net leverage reduced to 3.0x.

Outlook and guidance

• 2024 guidance: organic revenue growth of 4%-6%, total revenue growth of 5%-7%, adjusted EBITDA of $195M-$205M, adjusted EPS of $0.37-$0.42, and adjusted free cash flow of $65M-$85M.

• Medical segment expected to see low single-digit growth due to international headwinds; Technologies segment forecasted for mid-single-digit growth.

• Margin expansion initiatives and procurement improvements expected to drive 150-300 basis points of EBITDA margin improvement over three years.

• Management expects adequate liquidity for the next 12 months, supported by $123.8M in cash and $72.2M available on the revolver.

• Expected closure of lasers business to reduce organic revenue growth by ~30 basis points.